MEDDIC Qualification

A disciplined way to qualify enterprise sales opportunities by testing whether the buyer has measurable value, authority, criteria, process, pain, and a real internal champion.

Also known as: MEDDICC, MEDDPICC

MEDDIC looks like sales jargon until the first enterprise pipeline review where the biggest deal has no economic buyer, no urgent pain, and no one inside the account fighting for it. The acronym is blunt because the job is blunt: it forces a founder, sales lead, or investor to ask whether an opportunity is real before the company spends scarce time on it. In a sales-led startup, that distinction decides whether the forecast is revenue in motion or a spreadsheet full of hopeful logos.

Context

This pattern belongs in the growth-scaling stage, when a startup has moved beyond founder conversations and needs a repeatable enterprise sales process. The go-to-market motion is sales-led, the deals are large enough to justify human selling, and the buyer usually includes a committee, procurement, legal, security, and at least one internal sponsor.

At that stage, raw pipeline becomes dangerous. A CRM can hold every conversation a rep opens, every pilot a founder starts, and every friendly logo that took a meeting. None of that means the company has qualified opportunity. MEDDIC is the qualification discipline that sits underneath pipeline coverage and sales velocity: before the team counts a deal in the forecast, it checks whether the deal has passed the six tests that make it worth carrying.

The name comes from enterprise software sales in the 1990s, commonly traced to PTC. The base acronym is Metrics, Economic Buyer, Decision Criteria, Decision Process, Identify Pain, Champion. MEDDICC adds Competition. MEDDPICC adds Paper Process and Competition. The variants matter, but the underlying test is the same: a deal isn’t qualified because someone is interested. It is qualified when the buyer’s value, authority, process, pain, and internal advocacy are specific enough to make a purchase plausible.

Problem

Enterprise startups routinely confuse activity with sales capacity. A founder sees a large account in discovery, a mid-level champion sending positive notes, and a pilot that keeps expanding. The CRM value goes up, the board deck shows coverage, and the company spends engineering and sales time as if the opportunity were closeable.

The failure appears later. The buyer never had budget authority. Legal and procurement were never mapped. The business pain was nice-to-have, not urgent. The champion liked the product but couldn’t make the company buy it. The deal slips, the forecast misses, and the startup has spent runway on an opportunity that was never properly qualified.

Forces

• Pipeline volume versus pipeline truth. A full CRM reassures a team and its board, but counting unqualified opportunities makes the forecast less honest.
• Champion enthusiasm versus buyer authority. A user can love the product and still have no budget, no decision power, and no path to the person who does.
• Founder optimism versus sales discipline. Early-stage companies need conviction, but enterprise sales punishes optimism that is not tied to buyer evidence.
• Speed versus disqualification. Walking away from a large logo feels painful, especially when pipeline is thin, but slow bad deals are more expensive than fast noes.
• Process depth versus startup capacity. MEDDIC adds rigor, but every qualification field takes time to discover; the process has to be lighter than the deal value it protects.

Solution

Qualify each enterprise opportunity against the MEDDIC fields before treating it as forecastable pipeline. The method turns a vague “good account” into six deal-level questions:

The practical move is to make those questions part of the deal review, not an after-the-fact explanation. If the opportunity lacks an economic buyer, it stays out of the forecast or is marked as unqualified. If the buyer has no decision criteria, the next action is to discover them, not to send another proposal. If the pain is vague, the team keeps learning or walks away. MEDDIC works because it changes what the company rewards: evidence of a buying process, not evidence of conversation.

MEDDPICC extends the same discipline for more complex enterprise deals. Paper Process asks how contracts, security review, procurement, legal redlines, and vendor onboarding actually move. Competition asks what the buyer is comparing the startup against, including the most common competitor: no decision. Those additions are often the difference between a startup that knows the buyer wants the product and one that knows whether the buyer can buy it this quarter.

How It Plays Out

A Series A infrastructure startup is selling a six-figure platform to banks. The forecast shows a $400,000 opportunity with a recognizable name, and the champion says the product is “exactly what we need.” Without MEDDIC, that deal probably sits in late-stage pipeline. With MEDDIC, the review is harsher. The team has no economic buyer, only a senior architect. It has no decision criteria, only a list of technical preferences. It has no paper process, and bank vendor onboarding usually takes three months. The opportunity may be promising, but it isn’t closeable this quarter. It leaves the forecast until the buyer and process are real.

The opposite case is smaller but healthier. A mid-market account has a quantified pain: the buyer is spending $80,000 a quarter on manual compliance review. The VP who owns the budget is in the room. The decision criteria are written down: audit trail, integration with the existing workflow, SOC 2, and payback inside twelve months. Procurement has a known path, and the champion is measured on reducing review time. The deal may still lose, but it deserves a forecast slot because the buying process exists.

The investor version comes during diligence. A founder reports $3M of late-stage pipeline, enough to support next year’s plan. The investor asks for the MEDDIC fields by opportunity. Half the pipeline falls away: champions without budget, pilots without criteria, deals with no procurement path, opportunities where “pain” means curiosity. The remaining $1.4M is less impressive on the slide and more useful in reality. The investor has not made a sales-methodology point. They have learned which revenue is likely enough to underwrite.

Consequences

Using MEDDIC changes the sales conversation from “how much pipeline do we have?” to “which opportunities have enough buyer evidence to deserve capacity?”

Benefits. The framework makes qualification explicit, so founders stop funding expensive enterprise work on vague interest. It improves forecast quality by cleaning the numerator in pipeline coverage and the opportunity count in sales velocity. It gives investors a concrete diligence path for revenue claims. It also helps talent read a sales-led company: a team that can name its buyer, process, pain, and champion is more likely to have a real revenue engine than one celebrating every pilot as pipeline.

Liabilities. MEDDIC can become heavy for deals that don’t need it. A low-price self-serve product, a simple inside-sales motion, or a transactional buyer may not justify a full enterprise qualification process. The framework can also harden into bureaucracy if managers score fields instead of inspecting evidence. And it can create false precision: a rep can write an economic buyer’s name into a field without having access to that person. The method works only when the team treats missing evidence as a reason to change the deal, not as paperwork to complete.

Related Articles

Sources

• HubSpot, A Step-by-Step Guide to the MEDDIC Sales Qualification Process — defines MEDDIC as a sales qualification framework and names the six base dimensions.
• Salesforce, BANT vs. MEDDIC — contrasts MEDDIC with lighter qualification methods and frames it for complex B2B buyer journeys.
• Apollo, MEDDPICC Sales Qualification — describes the MEDDPICC extension and ties it to deal reviews, pipeline health, and forecast accuracy.
• MEDDPICCR, What Is MEDDIC? — gives the specialist-methodology treatment, including the PTC-origin story and the relationship among MEDDIC, MEDDICC, and MEDDPICC.
• Closing Foundry, MEDDIC Framework — gives the founder-facing interpretation of the criteria as a test for whether an opportunity is real, funded, and winnable.